Similar articles

• [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

  Chapple C. Chapple C. Urologe A. 2007 Apr;46(4):422, 424-6; author reply 426, 428. doi: 10.1007/s00120-007-1325-6. Urologe A. 2007. PMID: 17384923 German. No abstract available.
• [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

  Goepel M. Goepel M. Urologe A. 2006 Jul;45(7):847-51. doi: 10.1007/s00120-006-1121-8. Urologe A. 2006. PMID: 16816976 German. No abstract available.
• Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.

  Hart WM, Abrams P, Munro V, Retsa P, Nazir J. Hart WM, et al. J Med Econ. 2013 Oct;16(10):1246-54. doi: 10.3111/13696998.2013.829079. Epub 2013 Sep 11. J Med Econ. 2013. PMID: 23885660
• Pharmacologic management of overactive bladder.

  Lam S, Hilas O. Lam S, et al. Clin Interv Aging. 2007;2(3):337-45. Clin Interv Aging. 2007. PMID: 18044184 Free PMC article. Review.
• The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly.

  Ulahannan D, Wagg A. Ulahannan D, et al. Clin Interv Aging. 2009;4:191-6. doi: 10.2147/cia.s4233. Epub 2009 May 14. Clin Interv Aging. 2009. PMID: 19503781 Free PMC article. Review.